1. Known hypersensitivity to blood products <br/ >2. Receipt of Pooled Immunoglobulin in last 30 days <br/ >3. Participating in any other clinical trial <br/ >4. Contraindications to blood products <br/ >5. Pregnant or Breast feeding women <br/ >6. In the opinion of the site investigator or primary clinical care team, anticipated to die within 48 hours. <br/ >7.On mechanical ventilation for more than 7 days <br/ >8.Acute or chronic disease/illness that, in the opinion of the site investigator, has an expected life expectancy of less than 28 days unrelated to COVID-19 induced pneumonia (e.g. stage IV malignancy, neurodegenerative disease, anoxic brain injury, etc.) <br/ >9. Respiratory failure caused by illness other than SARS-CoV-2. <br/ >10 . Other documented uncontrolled infection <br/ >11. Severe DIC,TTP, or antithrombin III deficiency needing factor replacement, FFP, cryoprecipitate. <br/ >12. Active intracranial bleeding. <br/ >13. Clinically significant myocardial ischemia. <br/ > <br/ >

1. Known hypersensitivity to blood products <br/ >2. Receipt of Pooled Immunoglobulin in last 30 days <br/ >3. Participating in any other clinical trial <br/ >4. Contraindications to blood products <br/ >5. Pregnant or Breast feeding women <br/ >6. In the opinion of the site investigator or primary clinical care team, anticipated to die within 48 hours. <br/ >7.On mechanical ventilation for more than 7 days <br/ >8.Acute or chronic disease/illness that, in the opinion of the site investigator, has an expected life expectancy of less than 28 days unrelated to COVID-19 induced pneumonia (e.g. stage IV malignancy, neurodegenerative disease, anoxic brain injury, etc.) <br/ >9. Respiratory failure caused by illness other than SARS-CoV-2. <br/ >10 . Other documented uncontrolled infection <br/ >11. Severe DIC,TTP, or antithrombin III deficiency needing factor replacement, FFP, cryoprecipitate. <br/ >12. Active intracranial bleeding. <br/ >13. Clinically significant myocardial ischemia. <br/ > <br/ >

N/A

N/A

1. Known hypersensitivity to blood products <br/ >2. Receipt of Pooled Immunoglobulin in last 30 days <br/ >3. Participating in any other clinical trial <br/ >4. Contraindications to blood products <br/ >5. Pregnant or Breast feeding women <br/ >6. In the opinion of the site investigator or primary clinical care team, anticipated to die within 48 hours. <br/ >7.On mechanical ventilation for more than 7 days <br/ >8.Acute or chronic disease/illness that, in the opinion of the site investigator, has an expected life expectancy of less than 28 days unrelated to COVID-19 induced pneumonia (e.g. stage IV malignancy, neurodegenerative disease, anoxic brain injury, etc.) <br/ >9. Respiratory failure caused by illness other than SARS-CoV-2. <br/ >10 . Other documented uncontrolled infection <br/ >11. Severe DIC,TTP, or antithrombin III deficiency needing factor replacement, FFP, cryoprecipitate. <br/ >12. Active intracranial bleeding. <br/ >13. Clinically significant myocardial ischemia. <br/ > <br/ >

1. Known hypersensitivity to blood products <br/ >2. Receipt of Pooled Immunoglobulin in last 30 days <br/ >3. Participating in any other clinical trial <br/ >4. Contraindications to blood products <br/ >5. Pregnant or Breast feeding women <br/ >6. In the opinion of the site investigator or primary clinical care team, anticipated to die within 48 hours. <br/ >7.On mechanical ventilation for more than 7 days <br/ >8.Acute or chronic disease/illness that, in the opinion of the site investigator, has an expected life expectancy of less than 28 days unrelated to COVID-19 induced pneumonia (e.g. stage IV malignancy, neurodegenerative disease, anoxic brain injury, etc.) <br/ >9. Respiratory failure caused by illness other than SARS-CoV-2. <br/ >10 . Other documented uncontrolled infection <br/ >11. Severe DIC,TTP, or antithrombin III deficiency needing factor replacement, FFP, cryoprecipitate. <br/ >12. Active intracranial bleeding. <br/ >13. Clinically significant myocardial ischemia. <br/ > <br/ >